Objective: This study aims to investigate the effectiveness of the multiparametric prostate magnetic resonance imaging (Mp-MRI), reporting and data system (PIRADS) guide used for diagnosis in patients with clinically suspected prostate cancer.

Materials and Methods: Between January 2016 and March 2019, patients with positive examination and laboratory findings in prostate cancer were included in the study (n: 52). The cases were evaluated with 3Tesla Mp-MRI before the biopsy. PIRADS scoring was done and the scores obtained were compared with the histopathological results. The sensitivity, specificity, and positive and negative predictive values of Mp-MRI were calculated. Besides, the relationship between Apparent diffusion coefficient (ADC) measurement, prostate-specific antigen (PSA) increase, and PSA concentration with cancer was investigated.

Results: The mean ages were 65.1±5.8. 5 patients were scored as PIRADS 2, 9 patients PIRADS 3, 18 patients PIRADS 4, and 20 patients PIRADS 5 in radiologically. 28 patients were reported as adenocancer, 3 patients’ prostate atypical small acinar proliferation (ASAP), 9 patients’ benign prostatic hyperplasia (BPH), 4 patients’ chronic prostatitis, and 3 patients as other inflammatory reactions histopathologically. The sensitivity, specificity, and negative and positive predictive values were calculated as 67.8%, 66.6%, 64%, and 70%, respectively. A positive correlation was found between apparent diffusion coefficient (ADC) measurement, PSA volume and PSA density with the cancer.

Conclusion:The biopsy is still the most used method in patients with clinical suspicion for prostate cancer. However, it is an invasive procedure with a high rate of false negativity. The preferring of PIRADS scoring with Mp-MRI is a non-invasive and beneficial modality in terms of diagnosis, correct biopsy indication, and treatment.